drugset / Trial / NCT05911464
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.
Timeline
- Start
- 2023-03-02
- Primary completion
- 2025-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10386 | Unknown | 10 mg | — |